mTOR signaling: PLD takes center stage

Cell Cycle

Volumn 7, Issue 20, 2008, Pages 3118-3123

  Sun, Yuting ^a   Chen, Jie ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Amino acids; Cell growth; FKBP38; Phosphatidic acid; Rheb; Tuberous sclerosis complex (TSC); Vps34

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDIC ACID; PHOSPHOLIPASE D; PHOSPHOLIPASE D1; PROTEIN MTORC1; PROTEIN MTORC2; RHEB PROTEIN; UNCLASSIFIED DRUG;

CELL FUNCTION; ENZYME ACTIVITY; HUMAN; NONHUMAN; NUTRIENT; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 54149107123     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.20.6881     Document Type: Review

References (96)

1. Wullschleger S, Loewith R and Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84.
2. Hay N and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45.
3. Guertin DA and Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22.
4. Erbay E, Kim JE and Chen J. In Book 2005, Amino acid-sensing mTOR signaling (eds. Zempleni J and Dakshinamurti K) 353-380 (CRC Press).
5. Martin DE and Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005; 17:158-66.
6. Sarbassov DD, Ali SM and Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17:596-603.
7. Gingras AC, Raught B and Sonenberg N. Regulation of translation initiation by FRAP/ mTOR. Genes Dev 2001; 15:807-26.
8. Fumagalli S and Thomas G. In Book 2000, S6 phosphorylation and signal transduction (eds. Sonenberg N, Hershey JWB and Mathews MB.) 695-718 (Cold Spring Harbor Lab Press, Cold Spring Harbor).
9. Gingras AC, Raught B and Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68:913-63.
10. Fingar DC and Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151-71.
11. Cheadle JP, Reeve MP, Sampson JR and Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 2000; 107:97-114.
12. Marygold SJ and Leevers SJ. Growth Signaling: TSC Takes Its Place. Curr Biol 2002; 12:785-7.
13. McManus EJ and Alessi DR. TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nat Cell Biol 2002; 4:214-6.
14. Inoki K, et al. TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth. Cell 2006; 126:955-68.
15. Lee DF, et al. IKKbeta Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway. Cell 2007; 130:440-55.
16. Manning BD and Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003; 28:573-6.
17. Li Y, Corradetti MN, Inoki K and Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004; 29:32-8.
18. Long X, Lin Y, Ortiz-Vega S, Yonezawa K and Avruch J. Rheb Binds and Regulates the mTOR Kinase. Curr Biol 2005; 15:702-13.
19. Long X, Ortiz-Vega S, Lin Y and Avruch J. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 2005; 280:23433-6. Epub 2005.
20. Smith EM, Finn SG, Tee AR, Browne GJ and Proud CG. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 2005; 280:18717-27.
21. Long X, Lin Y, Ortiz-Vega S, Busch S and Avruch J. The rheb switch 2 segment is critical for signaling to target of rapamycin complex 1. J Biol Chem 2007; 282:18542-51. Epub 2007.
22. Bai X, et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007; 318:977-80.
23. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A and Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294:1942-5.
24. Veverka V, et al. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 2007; 27:585-95.
25. Chen Y, Zheng Y and Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003; 22:3937-42.
26. Hornberger TA, et al. The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. Proc Natl Acad Sci USA 2006; 103:4741-6.
27. Xu Y, Fang Y, Chen J and Prestwich GD. Activation of mTOR signaling by novel fluoromethylene phosphonate analogues of phosphatidic acid. Bioorg Med Chem Lett 2004; 14:1461-4.
28. Lehman N, et al. Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR. Faseb J 2007; 21:1075-87.
29. Exton JH. Regulation of phospholipase D. Biochim Biophys Acta 1999; 1439:121-33.
30. Frohman MA, Sung TC and Morris AJ. Mammalian phospholipase D structure and regulation. Biochim Biophys Acta 1999; 1439:175-86.
31. Ballou LM, Jiang YP, Du G, Frohman MA and Lin RZ. Ca(2+)- and phospholipase D-dependent and -independent pathways activate mTOR signaling. FEBS Lett 2003; 550:51-6.
32. Fang Y, et al. PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr Biol 2003; 13:2037-44.
33. Kam Y and Exton JH. Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid. FASEB J 2004; 18:311-9.
34. Foster DA. Regulation of mTOR by phosphatidic acid? Cancer Res 2007; 67:1-4.
35. Sun Y, et al. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci USA 2008; 105:8286.
36. Ha SH, et al. PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals. Cell Signal 2006; 18:2283-91. Epub 2006.
37. Chou MM and Blenis J. The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. Cell 1996; 85:573-83.
38. Coon M, et al. Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells. Mol Cancer Ther 2003; 2:1067-78.
39. Avila-Flores A, Santos T, Rincon E and Merida I. Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. J Biol Chem 2005; 280:10091-9. Epub 2005.
40. Dan HC, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002; 277:35364-70.
41. Huang P, Altshuller YM, Hou JC, Pessin JE and Frohman MA. Insulin-stimulated plasma membrane fusion of Glut4 glucose transporter- containing vesicles is regulated by phospholipase D1. Mol Biol Cell 2005; 16:2614-23. Epub 2005.
42. Inoki K, Li Y, Zhu T, Wu J and Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648-57.
43. Kotter K, et al. Activation of astroglial phospholipase D activity by phorbol ester involves ARF and Rho proteins. Biochim Biophys Acta 2000; 1485:153-62.
44. Potter CJ, Pedraza LG and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002; 4:658-65.
45. Slaaby R, Du G, Altshuller YM, Frohman MA and Seedorf K. Insulin-induced phospholipase D1 and phospholipase D2 activity in human embryonic kidney-293 cells mediated by the phospholipase C gamma and protein kinase C alpha signalling cascade. Biochem J 2000; 351:613-9.
46. Tee AR, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002; 99:13571-6.
47. Sethu S, Mendez-Corao G and Melendez AJ. Phospholipase D1 plays a key role in TNFalpha signaling. J Immunol 2008; 180:6027-34.
48. Ma L, Chen Z, Erdjument-Bromage H, Tempst P and Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121:179-93.
49. Ma L, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 2007; 67:7106-12.
50. Roux PP, Ballif BA, Anjum R, Gygi SP and Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 2004; 101:13489-94. Epub 2004.
51. Shi M, Zheng Y, Garcia A, Xu L and Foster DA. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Letters 2007; 258:268-75.
52. Garcia A, et al. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase d activity in human cancer cells. Clin Cancer Res 2008; 14:4267-74.
53. Vo M, et al. Phospholipase D Stimulation by Receptor Tyrosine Kinases Mediated by Protein Kinase C and a Ras/Ral Signaling Cascade. J Biol Chem 1999; 274:34691-8.
54. Yoon M-S, Koo JB, Hwang J-H, Lee KS and Han J-S. Activation of phospholipase D by 8-Br-cAMP occurs through novel pathway involving Src, Ras and ERK in human endometrial stromal cells. FEBS Letters 2005; 579:5635-42.
55. Watanabe H, et al. Essential Role for Phospholipase D2 Activation Downstream of ERK MAP Kinase in Nerve Growth Factor-stimulated Neurite Outgrowth from PC12 Cells. J Biol Chem 2004; 279:37870-7.
56. Chen J and Fang Y. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 2002; 64:1071.
57. Byfield MP, Murray JT and Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 2005; 280:33076-82. Epub 2005.
58. Nobukuni T, et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 2005; 102:14238-43. Epub 2005.
59. 2+/CaM signaling to hVps34. Cell Metab 2008; 7:456-65.
60. Fruman DA, Meyers RE and Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998; 67:481-507.
61. Lemmon MA. Phosphoinositide recognition domains. Traffic 2003; 4:201-13.
62. Frohman MA and Morris AJ. Phospholipase D structure and regulation. Chem Phys Lipids 1999; 98:127-40.
63. Im E, et al. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 2002; 21:6356-65.
64. Smith EM, Finn SG, Tee AR, Browne GJ and Proud CG. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 2005; 280:18717-27.
65. Roccio M, Bos JL and Zwartkruis FJ. Regulation of the small GTPase Rheb by amino acids. Oncogene 2006; 25:657-64.
66. Sancak Y, et al. The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1. Science 2008; 320:1496-501.
67. Kim E, Goraksha-Hicks P, Li L, Neufeld TP and Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 2008; 10:935-45. Epub 2008.
68. Meier KE, Gibbs TC, Knoepp SM and Ella KM. Expression of phospholipase D isoforms in mammalian cells. Biochem Biophys Acta 1999; 1439:199-213.
69. Colley WC, et al. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr Biol 1997; 7:191-201.
70. Freyberg Z, et al. Intracellular localization of phospholipase D1 in mammalian cells. Mol Biol Cell 2001; 12:943-55.
71. Du G, Huang P, Liang BT and Frohman MA. Phospholipase D2 localizes to the plasma membrane and regulates angiotensin II receptor endocytosis. Mol Biol Cell 2004; 15:1024-30. Epub 2004.
72. Yoon MS and Chen J. PLD regulates myoblast differentiation through the mTOR-IGF2 pathway. J Cell Sci 2008; 121:282-9.
73. Schalm SS, Fingar DC, Sabatini DM and Blenis J. TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function. Curr Biol 2003; 13:797-806.
74. Nojima H, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003; 278:15461-4.
75. Choi KM, McMahon LP and Lawrence JC Jr. Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor. J Biol Chem 2003; 278:19667-73.
76. Liscovitch M, Czarny M, Fiucci G and Tang X. Phospholipase D: molecular and cell biology of a novel gene family. Biochem J 2000; 345:401-15.
77. Kam Y and Exton JH. Phospholipase D activity is required for actin stress fiber formation in fibroblasts. Mol Cell Biol 2001; 21:4055-66.
78. Foster DA and Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res 2003; 1:789-800.
79. Buchanan FG, et al. Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci USA 2005; 102:1638-42. Epub 2005.
80. Chen Y, Rodrik V and Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005; 24:672-9.
81. Zheng Y, et al. Phospholipase D couples survival and migration signals in stress response of human cancer cells. J Biol Chem 2006; 281:15862-8. Epub 2006.
82. Leseux L, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108:4156-62.
83. Wang J, et al. Restricted epithelial proliferation by lacritin via PKCalpha-dependent NFAT and mTOR pathways. J Cell Biol 2006; 174:689-700.
84. Kenji Ohguchi Y. B. Y. N. Y. A. Y. N. Negative regulation of melanogenesis by phospholipase D1 through mTOR/p70 S6 kinase 1 signaling in mouse B16 melanoma cells. Journal of Cellular Physiology 2005; 205:444-51.
85. Ohguchi K, Banno Y, Akao Y and Nozawa Y. Involvement of phospholipase D1 in collagen type I production of human dermal fibroblasts. Biochemical and Biophysical Research Communications 2006; 348:1398-402.
86. Rudge SA and Engebrecht J. Regulation and function of PLDs in yeast. Biochim Biophys Acta 1999; 1439:167-74.
87. Pan D, Dong J, Zhang Y and Gao X. Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol 2004; 14:78-85.
88. Bjorklund M, et al. Identification of pathways regulating cell size and cell cycle progression by RNAi. Nature 2006; 439:1009-13.
89. LaLonde M, et al. A role for Phospholipase D in Drosophila embryonic cellularization. BMC Dev Biol 2006; 6:60.
90. LaLonde MM, et al. Regulation of phototransduction responsiveness and retinal degeneration by a phospholipase D-generated signaling lipid. J Cell Biol 2005; 169:471-9.
91. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ and Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007; 9:316-23. Epub 2007.
92. Wang L, Harris TE, Roth RA and Lawrence JC Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 2007; 282:20036-44. Epub 2007.
93. Oshiro N, et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 2007; 282:20329-39. Epub 2007.
94. Fonseca BD, Smith EM, Lee VH, MacKintosh C and Proud CG. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 2007; 282:24514-24. Epub 2007.
95. Sancak Y, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25:903-15.
96. Juhasz G, et al. The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in Drosophila J. Cell Biol 2008; 181:655-66.